A proposal for score assignment to characterize biological processes from mass spectral analysis of serum

Authors: Roder, Joanna, Net, Lelia, Oliveira, Carlos, Meyer, Krista, Asmellash, Senait, Kasimir-Bauer, Sabine, Pass, Harvey, Weber, Jeffrey, Roder, Heinrich, Grigorieva, Julia

Source: In Clinical Mass Spectrometry November 2020 18:13-26

Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests

Authors: Grigorieva, Julia, Asmellash, Senait, Oliveira, Carlos, Roder, Heinrich, Net, Lelia, Roder, Joanna

Source: In Clinical Mass Spectrometry January 2020 15:44-53

Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis

Authors: Leal, Ticiana A., Argento, Angela C., Bhadra, Krish, Hogarth, D. Kyle, Grigorieva, Julia, Hartfield, Rachel M., McDonald, Robert C., Bonomi, Philip D.

Source: Current medical research and opinion. 36(9):1497-1505

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100110686456.0x000001&indx=1&recIds=ETOCvdc_100110686456.0x000001

Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy

Authors: Grossi, Francesco, Genova, Carlo, Rijavec, Erika, Barletta, Giulia, Biello, Federica, Dal Bello, Maria Giovanna, Meyer, Krista, Roder, Joanna, Roder, Heinrich, Grigorieva, Julia

Source: In Lung Cancer March 2018 117:64-69

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Authors: Ascierto, Paolo, Capone, Mariaelena, Grimaldi, Antonio, Mallardo, Domenico, Simeone, Ester, Madonna, Gabriele, Roder, Heinrich, Meyer, Krista, Asmellash, Senait, Oliveira, Carlos, Roder, Joanna, Grigorieva, Julia

Source: Journal for immunotherapy of cancer. 7(1):1-8

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100190703956.0x000001&indx=1&recIds=ETOCvdc_100190703956.0x000001

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Authors: Gregorc, Vanesa, Novello, Silvia, Lazzari, Chiara, Barni, Sandro, Aieta, Michele, Mencoboni, Manlio, Grossi, Francesco, Pas, Tommaso De, de Marinis, Filippo, Bearz, Alessandra, Floriani, Irene, Torri, Valter, Bulotta, Alessandra, Cattaneo, Angela, Grigorieva, Julia, Tsypin, Maxim, Roder, Joanna, Doglioni, Claudio, Levra, Matteo Giaj, Petrelli, Fausto, Foti, Silvia, Viganò, Mariagrazia, Bachi, Angela, Roder, Heinrich

Source: In The Lancet Oncology June 2014 15(7):713-721

Method and system for determining whether a drug will be effective on a patient with a disease

A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer

Authors: Stinchcombe, Thomas E., Roder, Joanna, Peterman, Amy H., Grigorieva, Julia, Lee, Carrie B., Moore, Dominic T., Socinski, Mark A.

Source: In Journal of Thoracic Oncology April 2013 8(4):443-451

Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial

Authors: Carbone, David P., Ding, Keyue, Roder, Heinrich, Grigorieva, Julia, Roder, Joanna, Tsao, Ming-Sound, Seymour, Lesley, Shepherd, Frances A.

Source: In Journal of Thoracic Oncology November 2012 7(11):1653-1660

Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Authors: Lazzari, Chiara, Spreafico, Anna, Bachi, Angela, Roder, Heinrich, Floriani, Irene, Garavaglia, Daniela, Cattaneo, Angela, Grigorieva, Julia, Viganò, Maria Grazia, Sorlini, Cristina, Ghio, Domenico, Tsypin, Maxim, Bulotta, Alessandra, Bergamaschi, Luca, Gregorc, Vanesa

Source: In Journal of Thoracic Oncology January 2012 7(1):40-48

VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Authors: Gautschi, Oliver, Dingemans, Anne-Marie, Crowe, Susanne, Peters, Solange, Roder, Heinrich, Grigorieva, Julia, Roder, Joanna, Zappa, Francesco, Pless, Miklos, Brutsche, Martin, Baty, Florent, Bubendorf, Lukas, Hsu Schmitz, Shu-Fang, Na, Kyung-Jae, Carbone, David, Stahel, Rolf, Smit, Egbert

Source: In Lung Cancer October 2012

Method and system for determining whether a drug will be effective on a patient with a disease

Monitoring treatment of head and neck cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples

Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples

Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy

Method and system for determining whether a drug will be effective on a patient with a disease

Monitoring treatment of Head and Neck cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples

Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples

Monitoring treatment of head and neck cancer patients with drugs EGFR pathway using mass spectrometry of patient samples

Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples